August 29 | 2025
CEO Nathaniel Hutley presents a strategic update on 2cureX’s new Website Blog.
Read more
August 21 | 2025
2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2025.
Read more
July 11 | 2025
Improved communication from 2cureX AB
Read more
July 2 | 2025
Correction: CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.
Read more
July 1 | 2025
2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG.
Read more
June 27 | 2025
KOMMUNIKÉ FRÅN ÅRSSTÄMMAN I 2CUREX AB (PUBL)
Read more
June 13 | 2025
CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.
Read more
May 30 | 2025
KALLELSE TILL ÅRSSTÄMMA I 2CUREX AB (publ).
Read more
May 30 | 2025
NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ).
Read more
May 29 | 2025
RELEASE OF THE 2CUREX AB (PUBL) ANNUAL REPORT
Read more
May 29 | 2025
PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (PUBL)
Read more
May 22 | 2025
2cureX appoints Mangold Fondkommission AB as new Certified Adviser
Read more
May 20 | 2025
2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy
Read more
May 15 | 2025
2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap
Read more
April 14 | 2025
EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ)
Read more
February 27 | 2025
2cureX publishes interim report for the second half year of 2024
Read more
January 20 | 2025
2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE
Read more
January 10 | 2025
Correction: 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE
Read more